NCT00027586 2018-10-31Imatinib Mesylate in Treating Patients With Metastatic MelanomaM.D. Anderson Cancer CenterPhase 2 Completed22 enrolled
NCT00074308 2018-06-20Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced CancersNational Cancer Institute (NCI)Phase 1/2 Completed40 enrolled 10 charts
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled
NCT00470470 2014-12-23Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 2 Completed30 enrolled 7 charts
NCT00068783 2013-02-28S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerNational Cancer Institute (NCI)Phase 2 Completed40 enrolled
NCT00881049 2011-01-17Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic MelanomaPeking UniversityPhase 2 Completed1 enrolled